Exosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United States
February 23, 2018 07:47 ET
|
Exosome Diagnostics
Boston, MA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. summarized the impact of a series of recent announcements about contracts to provide laboratory services and ExoDx®...
Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed
February 01, 2018 07:35 ET
|
Exosome Diagnostics
Waltham, MA, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the US
January 25, 2018 07:30 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., today announced that it has entered into a preferred provider network agreement with America’s Choice Provider Network...
Exosome Diagnostics Places Early Access Shahky™ Exosomal Protein Detection System at MGH Center for Systems Biology
January 09, 2018 07:46 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has placed an Early Access version of its commercial Shahky system, which quantitively measures exosomal proteins, at...
Exosome Diagnostics Announces Positive Coverage for EPI from Largest Payor in the Mid-Atlantic Region
January 08, 2018 13:15 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics announced today that the largest private payor in the Mid-Atlantic region has reached a positive coverage decision for its...
Exosome Diagnostics Places Its First Early Access Shahky System within a Top 15 Pharmaceutical Laboratory
January 08, 2018 07:56 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics has announced the placement of the world’s first system for exosome specific protein analysis, the Shahky system, within a large...
Exosome Diagnostics Launches National Sales Team to Support Flagship Test, ExoDx®Prostate(IntelliScore)
January 03, 2018 07:30 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Expounding upon the very successful regional introduction of the ExoDx Prostate(IntelliScore), or EPI, Exosome Diagnostics is thrilled to announce...
Exosome Diagnostics Publishes a Study Demonstrating Superior Performance of ExoLution™ Plus Liquid Biopsy Platform in Lung Cancer
December 19, 2017 07:51 ET
|
Exosome Diagnostics
Waltham, MA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., recently published a study in the Journal Annals of Oncology, of EGFR Liquid Biopsy detection in patients with Non-Small...
Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network
December 04, 2017 07:33 ET
|
Exosome Diagnostics
Boston, MA, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that it has executed an agreement for coverage of its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore Test
November 27, 2017 08:16 ET
|
Exosome Diagnostics
Boston, MA, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the national Medicare price for its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore),...